Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

crowdsourcing

- PMLiVE

World Atopic Eczema Day 2023: Almirall unveils awareness campaign

The inflammatory skin disease is estimated to affect 4.4% of adults in the EU

- PMLiVE

LEO Pharma to acquire Timber Pharmaceuticals in deal worth up to $36m

The transaction gives LEO access to Timber’s lead investigational candidate, TMB-001

- PMLiVE

NICE recommends Amryt’s Filsuvez treatment for epidermolysis bullosa

Approximately 670 people in England are expected to benefit from the skin-wound-healing treatment

- PMLiVE

AbbVie doses first patient in phase 3 study of Rinvoq in hidradenitis suppurativa

The long-term inflammatory skin condition affects an estimated 1% of the global population

- PMLiVE

Incyte shares positive results for Opzelura cream in children with atopic dermatitis

Two to three million children aged two to 11 years in the US are affected by atopic dermatitis

- PMLiVE

Almirall’s Ilumetri shown to improve well-being of patients with plaque psoriasis

Almost 77% of psoriasis patients report that the condition negatively affects their well-being

- PMLiVE

Galderma’s nemolizumab shows promise in phase 3 prurigo nodularis trial

The condition affects more than 70 out of every 100,000 adults aged 18 to 64 years in the US

- PMLiVE

Janssen announces positive phase 2b results for JNJ-2113 in plaque psoriasis

The immune-mediated disease is estimated to affect more than 125 million people worldwide

- PMLiVE

Boehringer’s spesolimab shows promise in generalised pustular psoriasis prevention

The therapy prevented flares in patients with the chronic skin disease for over 48 weeks

- PMLiVE

Bristol Myers Squibb’s Sotyktu recommended by NICE for plaque psoriasis

An estimated 1.8 million people in the UK are affected by some form of the condition

- PMLiVE

Sanofi’s amlitelimab shows promise in phase 2b atopic dermatitis trial

The inflammatory skin disease affects an estimated 16.5 million adults in the US

- PMLiVE

Almirall launches mini-series to highlight impact of psoriasis on patient well-being

Almost 77% of psoriasis patients report that the condition negatively affects their well-being

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links